I. AMENDMENTS

Amendments to the Claims:

Please replace all prior listing of claims with the following listing:

1. to 16. Canceled.

17. (Previously Presented) A monoclonal antibody which specifically binds to a Aβ11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length Aβ1-40/42 peptide.

18. (Presently Amended) The monoclonal antibody of claim 17, wherein said monoclonal antibody binds to human Aβ11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids.

19. (Presently Amended) The monoclonal antibody of claim 17, wherein said monoclonal antibody binds to mouse Aβ11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids.

20. (Previously Presented) The monoclonal antibody of claim 17, which is detectably labeled.

21. (Previously Presented) The monoclonal antibody of claim 21, wherein said detectable label is a radiolabel, an enzyme label, a luminescent label or a fluorescent label.

22. (Previously Presented) The monoclonal antibody of claim 17, wherein said antibody is immobilized on a carrier.

23. (Previously Presented) The monoclonal antibody of claim 17, which is mouse.

24. (Previously Presented) The monoclonal antibody of claim 17, which is chimeric.

25. (Previously Presented) The monoclonal antibody of claim 17, which is humanized.

26. (Previously Presented) The monoclonal antibody of claim 17, which is produced by the hybridoma cell with the accession numbers LMBP 5896CB.

27. (Previously Presented) The monoclonal antibody of claim 17, which is produced by the hybridoma cell with the accession number LMBP 5897CB.

28. (Previously Presented) A hybridoma which produces the monoclonal antibody of claim 17.

29. (Previously Presented) The hybridoma of claim 28 which has the accession number LMBP 5896CB.

30. (Previously Presented) The hybridoma of claim 28 which has the accession number LMBP 5897CB.

31. (Previously Presented) A method for the determination or detection of Aβ11-x peptide in a sample, the method comprising contacting the sample with the antibody of claim 17, and determining whether an immune complex is formed between the antibody and the Aβ11-x peptide.

32. (Previously Presented) The method of claim 31, wherein said sample is a tissue sample.

33. (Previously Presented) The method of claim 31, wherein said sample is a bodily fluid.

34. (Previously Presented) The method of claim 33, wherein said bodily fluid is selected from the group consisting of CSF, blood, plasma, serum and urine.

35. (Previously Presented) A method for the diagnosis of Alzheimer's disease, comprising:

obtaining a sample from a subject in need of said diagnosis;
contacting said sample with an effective amount of said antibody of claim 20;
detecting said label to determine the presence of Aβ11-x peptides in said sample; and
comparing an amount of Aβ11-x peptides in said sample to an amount of Aβ11-x peptides in a control, wherein an increased amount of Aβ11-x peptides in said sample compared to the amount of Aβ11-x peptides in the control indicates the presence of Alzheimer's disease.

36. (Previously Presented) A diagnostic composition comprising said antibody of claim 17 and a pharmaceutically acceptable carrier.